Search Results - "Hua, Yijia"

The prognostic value of MKL1 in predicting breast cancer immune infiltrates and chemosensitivity by Hua, Yijia, Yang, Mengzhu

“…Megakaryocytic leukemia 1 (MKL1) acts as a transcription factor in the regulation of the immune system and is associated with cancer biology. However, its…”
Get full text

Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis by Yan, Xueqi, Xie, Yinghong, Yang, Fan, Hua, Yijia, Zeng, Tianyu, Sun, Chunxiao, Yang, Mengzhu, Huang, Xiang, Wu, Hao, Fu, Ziyi, Li, Wei, Jiao, Shiping, Yin, Yongmei

“…Breast cancer is a heterogeneous disease with a complex microenvironment consisting of tumor cells, immune cells, fibroblasts and vascular cells. These…”
Get full text

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study by Hua, Yijia, Li, Wei, Jin, Nan, Cai, Dongyan, Sun, Jie, Sun, Chunxiao, Yang, Fan, Wu, Xinyu, Huang, Xiang, Wang, Biyun, Yin, Yongmei

“…Background: Tyrosine kinase inhibitors (TKIs) are effective for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer…”
Get full text

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report by Jin, Nan, Sun, Chunxiao, Hua, Yijia, Wu, Xinyu, Li, Wei, Yin, Yongmei

“…Hemangioblastoma (HB) is a rare and highly vascularized tumor that originates from the central nervous system as well as other part of the body. They can…”
Get full text

Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2‐Positive Breast Cancer by Duan, Ningjun, Hua, Yijia, Yan, Xueqi, He, Yaozhou, Zeng, Tianyu, Gong, Jue, Fu, Ziyi, Li, Wei, Yin, Yongmei

“…Secondary trastuzumab resistance represents an evolutionary adaptation of HER2‐positive breast cancer during anti‐HER2 treatment. Most current studies have…”
Get full text

A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression by Yan, Xueqi, He, Yaozhou, Yang, Shikun, Zeng, Tianyu, Hua, Yijia, Bao, Shengnan, Yang, Fan, Duan, Ningjun, Sun, Chunxiao, Liang, Yan, Fu, Ziyi, Huang, Xiang, Li, Wei, Yin, Yongmei

“…As a key regulator of the DNA translesion synthesis (TLS) pathway, RAD18 is error-prone and contributes to the accumulation of DNA mutations. Our previous…”
Get full text

Risk Signature of Cancer-Associated Fibroblast-Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer by Sun, Chunxiao, Wang, Siwei, Zhang, Yuchen, Yang, Fan, Zeng, Tianyu, Meng, Fanchen, Yang, Mengzhu, Yang, Yiqi, Hua, Yijia, Fu, Ziyi, Li, Jun, Huang, Xiang, Wu, Hao, Yin, Yongmei, Li, Wei

“…Cancer-associated fibroblasts (CAFs) are key components in tumor microenvironment (TME). The secreted products of CAFs play important roles in regulating tumor…”
Get full text

The war between the immune system and the tumor - using immune biomarkers as tracers by Yang, Kai, Lu, Rongrong, Mei, Jie, Cao, Kai, Zeng, Tianyu, Hua, Yijia, Huang, Xiang, Li, Wei, Yin, Yongmei

“…Nowadays, immunotherapy is one of the most promising anti-tumor therapeutic strategy. Specifically, immune-related targets can be used to predict the efficacy…”
Get full text

Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study by Sun, Chunxiao, Hua, Yijia, Jin, Nan, Wang, Xiaojia, Huang, Jian, Wu, Xinyu, Zeng, Tianyu, Yan, Xueqi, Yang, Fan, Liang, Yan, Huang, Xiang, Li, Wei, Yin, Yongmei

“…The use of trastuzumab emtansine (T‐DM1) has revealed significant efficacy in HER2‐positive metastatic breast cancer (MBC). However, optimal therapeutic…”
Get full text

Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study by Bao, Shengnan, Jiang, Mengping, Wang, Xi, Hua, Yijia, Zeng, Tianyu, Yang, Yiqi, Yang, Fan, Yan, Xueqi, Sun, Chunxiao, Yang, Mengzhu, Fu, Ziyi, Huang, Xiang, Li, Jun, Wu, Hao, Li, Wei, Tang, Jinhai, Yin, Yongmei

“…Background With life span extending, breast cancer (BC) survivors may face the possibility of developing second primary cancer (SPC) and considerably shorten…”
Get full text

Abstract PO3-24-04: Altered epigenetic modifications and genome architecture reshape lipid metabolism during secondary trastuzumab resistance formation of HER2-positive breast cancer by Duan, Ningjun, Hua, Yijia, Yin, Yongmei

“…Abstract Title Altered epigenetic modifications and genome architecture reshape lipid metabolism during secondary trastuzumab resistance formation of…”
Get full text

Abstract 1711: Rearranged active enhancers and promoter-enhancer contacts promote lipid metabolic reprogramming during secondary trastuzumab adaptation of HER2 positive breast cancer by Duan, Ningjun, Hua, Yijia, Yin, Yongmei

“…Abstract Background: The development of secondary trastuzumab resistance signifies an evolutionary adaptation within HER2-positive breast cancer during…”
Get full text

Relationship between tRNA‐derived fragments and human cancers by Zeng, Tianyu, Hua, Yijia, Sun, Chunxiao, Zhang, Yuchen, Yang, Fan, Yang, Mengzhu, Yang, Yiqi, Li, Jun, Huang, Xiang, Wu, Hao, Fu, Ziyi, Li, Wei, Yin, Yongmei

“…tRNA‐derived fragments, a class of small noncoding RNAs (sncRNAs), have been identified in numerous studies in recent years. tRNA‐derived fragments are…”
Get full text

Greater physiological resistance to heat may favour an invasive freshwater turtle, enabling it to outcompete native species in a changing climate by Zhang, Changyi, Xu, Yuxuan, Hua, Yijia, Li, Peng, Storey, Kenneth B., Zhang, Wenyi

“…Climate warming and biological invasion can interact to affect ecosystems, and the results of such interactions depend on whether invaders show physiological…”
Get full text

Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study by Yin, Yongmei, Wu, Xinyu, Hua, Yijia, Sun, Chunxiao, Liang, Yan, Yang, Fan, Huang, Xiang, Li, Wei

“…e13051 Background: The group of HER2-negative accounts for 70-80% of breast cancer and effective treatments for heavily pretreated patients with HER2-negative…”
Get full text

Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion by Huang, Xiang, Hua, Yijia, Sun, Chunxiao, Yin, Yongmei

“…Human epidermal growth factor receptor 2 (HER2)-low breast cancer is a newly identified targetable subset of breast tumors, and its clinical characteristics…”
Get full text

Abstract PO3-24-05: Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer by Yin, Yongmei, Hua, Yijia, Duan, Ningjun, Sun, Chunxiao, Yang, Fan

“…Abstract Background Trastuzumab has shown great effectiveness in HER2 positive breast cancer treatment, but about 50% patients would undergo resistance during…”
Get full text

Tyrosine kinase inhibitors (TKIs) in trastuzumab emtansine (T-DM1) resistant HER2-positive metastatic breast cancer: A real-world study by Yin, Yongmei, Sun, Chunxiao, Hua, Yijia, Jiang, Mengping, Yang, Fan, Wu, Xinyu, Zeng, Tianyu, Bao, Shengnan, Liang, Yan, Huang, Xiang, Li, Wei

“…e13029 Background: Trastuzumab emtansine (T-DM1) has shown great effectiveness in treating HER2-positive metastatic breast cancer, but therapies subsequent to…”
Get full text

Abstract 3698: Epigenetic modification induced reprogramming of PUFAs-associated metabolism during trastuzumab resistance formation of HER2-positive breast cancer by Yin, Yongmei, Duan, Ningjun, Hua, Yijia, Hu, Shuang

“…Abstract Background: Secondary trastuzumab resistance seriously affects the treatment of HER2-positive breast cancer. Although studies have demonstrated…”
Get full text

Abstract P1-13-20: Reprogramming of oncogenic signal pathways and metabolism during trastuzumab resistance formation of HER2 positive breast cancer by Duan, Ningjun, Hua, Yijia, Hu, Shuang, Yin, Yongmei

“…Abstract Background The formation of resistance against trastuzumab deeply affects the treatment of HER2 positive breast cancer. Although studies have…”
Get full text